fda glp-1 enforcement news today compounding 2025 issued 25 warning letters to telehealth companies for FDA Warns GLP-1 Maker Over

Other weight-loss drugs are currently in development or regulatory approval stages, including: Once-daily GLP-1 pill orforglipron (Eli Lilly), which, when taken alongside a healthy diet and exercise, resulted in a 7.5% weight loss over 72 weeks on the 6mg dose, 8.4% loss with 12mg of orforglipron, and 11.2% loss with 36mg of orforglipron, as compared with 2.1% loss with placebo (funded by Eli Lilly

The lyophilisation process removes water, eliminating the primary medium through which chemical degradation occurs

No formation of oxaloacetate was detected in the experiments performed

Pattern of Inadequate Response to Safety Signals The progressive timeline of FDA warning label updates demonstrates what plaintiffs allege represents a systemic failure by manufacturers to act quickly when safety concerns emerged

Can you map the actual landscape